RxDoctor Payments Data

Stephen Koewler, MD

Internal Medicine · Evansville, INNPI 1467439844

Payments from drug & device makers

$516in general payments, 2019–2025

Across 34 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$118
  • Astellas Pharma US Inc$114
  • GSK$76
  • Takeda Pharmaceuticals U.S.A., Inc.$51
  • Novartis$38
  • Novo Nordisk$30
  • plus $89 from 7 others

What the payments were for

  • Food & beverage$40578%
  • Education$11222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$516 in reported general payments places this provider in the 65th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$212,139
Medicare patients
500
Services billed
2,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide93$123,067
OzempicSemaglutide98$113,004
JanuviaSitagliptin Phosphate107$112,326
EliquisApixaban89$83,763
JardianceEmpagliflozin89$68,428
XareltoRivaroxaban35$48,212
Fiasp FlextouchInsulin Aspart (Niacinamide)12$38,561
Repatha SureclickEvolocumab35$31,999
RybelsusSemaglutide26$24,222
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$23,944
Tresiba Flextouch U-100Insulin Degludec38$23,848
Tresiba Flextouch U-200Insulin Degludec36$23,041
InvokanaCanagliflozin30$22,856
SynthroidLevothyroxine Sodium199$19,362
FarxigaDapagliflozin Propanediol20$16,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$30$137,227124 claims
MerckJanuvia, Dulera$13$116,657120 claims
PfizerEliquis$12$83,76389 claims
Boehringer IngelheimJardiance, Stiolto Respimat$13$73,527100 claims
Johnson & JohnsonXarelto, Invokana$13$71,06865 claims
GSKTrelegy Ellipta$76$23,94429 claims
Astellas Pharma US IncMyrbetriq$114$14,91631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →